| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 82801 |
DiR Labeled Mannosylated Control Liposome (Neutral),DiR标记的甘露糖对照脂质体(中性) |
214 |
axc |
2024-12-24 |
| 82802 |
Bromo-PEG5-CH2COOtBu |
180 |
h |
2024-12-24 |
| 82803 |
DiD Labeled Mannosylated Control Liposome (Neutral),标记的甘露糖对照脂质体(中性) |
275 |
axc |
2024-12-24 |
| 82804 |
Bromo-PEG8-CH2COOtBu |
140 |
h |
2024-12-24 |
| 82805 |
DiA Labeled Mannosylated Control Liposome (Neutral),DiA标记的甘露糖对照脂质体(中性) |
180 |
axc |
2024-12-24 |
| 82806 |
Biotin-PEG3-CH2COOH,CAS号：1189560-96-0,生物素-PEG3-乙酸 |
250 |
h |
2024-12-24 |
| 82807 |
DiI Labeled Mannosylated Control Liposome (Neutral),DiI标记的甘露糖对照脂质体(中性) |
155 |
axc |
2024-12-24 |
| 82808 |
HO-PEG5-CH2COOH,CAS号：52026-48-9 |
146 |
h |
2024-12-24 |
| 82809 |
DiR Labeled Control Clodronate Liposome (Neutral),DiR标记的对照氯膦酸盐脂质体(中性) |
192 |
axc |
2024-12-24 |
| 82810 |
BocNH-PEG4-CH2CHO |
181 |
h |
2024-12-24 |
| 82811 |
DiD Labeled Control Clodronate Liposome (Neutral),DiD标记的对照氯膦酸盐脂质体(中性) |
202 |
axc |
2024-12-24 |
| 82812 |
m-PEG1000-CH2COOH |
204 |
h |
2024-12-24 |
| 82813 |
Benzyl-PEG2-CH2COOH,CAS号：91842-53-4 |
181 |
h |
2024-12-24 |
| 82814 |
DiA Labeled Control Clodronate Liposome (Neutral),DiA标记的对照氯膦酸盐脂质体(中性) |
175 |
axc |
2024-12-24 |
| 82815 |
Propanol-PEG6-CH2OH |
163 |
h |
2024-12-24 |
| 82816 |
DiI Labeled Control Clodronate Liposome (Neutral),DiI标记的对照氯膦酸盐脂质体(中性) |
173 |
axc |
2024-12-24 |
| 82817 |
Mannosylated Control Liposome,甘露糖对照脂质体 |
225 |
axc |
2024-12-24 |
| 82818 |
Propanol-PEG4-CH2OH,CAS号：156868-17-6 |
179 |
h |
2024-12-24 |
| 82819 |
Propanol-PEG3-CH2OH,CAS号：112935-57-6 |
163 |
h |
2024-12-24 |
| 82820 |
Mannosylated Clodronate Liposome,甘露糖基氯膦酸盐脂质体 |
314 |
axc |
2024-12-24 |
| 82821 |
Fmoc-Val-Cit-PAB，159858-22-7，抗体- 药物偶联物 |
184 |
zhn |
2024-12-24 |
| 82822 |
Propanol-PEG5-CH2OH |
153 |
h |
2024-12-24 |
| 82823 |
Control Liposome,对照脂质体 |
183 |
axc |
2024-12-24 |
| 82824 |
HO-PEG10-CH2COOH,CAS号：2250056-53-0 |
218 |
h |
2024-12-24 |
| 82825 |
Clodronate Liposome,氯膦酸盐脂质体 |
468 |
axc |
2024-12-24 |
| 82826 |
HO-PEG6-CH2COOH,CAS号：120394-66-3具体解释和潜在应用 |
273 |
h |
2024-12-24 |
| 82827 |
Amino-PEG11-CH2COOH具体解释和潜在应用 |
162 |
h |
2024-12-24 |
| 82828 |
0.5% Rhod-PE Encapsulated GL67:DOPE Liposomes,阳离子脂质体定制服务 |
246 |
axc |
2024-12-24 |
| 82829 |
Fmoc-Val-Cit-PAB，159858-22-7， 抗体- 药物偶联物 |
168 |
zhn |
2024-12-24 |
| 82830 |
HO-PEG24-CH2COOH具体解释和潜在应用 |
139 |
h |
2024-12-24 |
| 82831 |
0.5% NBD-DOPE Encapsulated GL67:DOPE Liposomes,0.5% NBD-DOPE封装的GL67:DOPE脂质体 |
167 |
axc |
2024-12-24 |
| 82832 |
m-PEG10-CH2COOH,CAS号：908258-58-2,十一氧杂三十四烷酸 |
177 |
h |
2024-12-24 |
| 82833 |
HO-PEG8-CH2COOH,CAS号：780006-30-6 |
200 |
h |
2024-12-24 |
| 82834 |
GL67:DOPE Liposomes,GL67与DOPE组成的脂质体 |
209 |
axc |
2024-12-24 |
| 82835 |
0.5% Rhod-PE Encapsulated DC-Chol:DOPE Liposomes,0.5% Rhod-PE封装的DC-Chol:DOPE脂质体 |
238 |
axc |
2024-12-24 |
| 82836 |
m-PEG9-CH2COOH,CAS号：405518-55-0 |
175 |
h |
2024-12-24 |
| 82837 |
Tos-PEG5-CH2COOtBu,CAS号：1949793-62-7 |
172 |
h |
2024-12-24 |
| 82838 |
0.5% NBD-DOPE Encapsulated DC-Chol:DOPE Liposomes,0.5% NBD-DOPE封装的DC-Chol:DOPE脂质体 |
490 |
axc |
2024-12-24 |
| 82839 |
Hydroxy-PEG4-CH2COOH,14-羟基-3,6,9,12-四氧杂癸酸,CAS号：70678-95-4 |
176 |
h |
2024-12-24 |
| 82840 |
DC-Chol:DOPE Liposomes,DC-Chol与DOPE组成的脂质体 |
441 |
axc |
2024-12-24 |
| 82841 |
Hydroxy-PEG2-CH2COOH,CAS号：51951-04-3 |
133 |
h |
2024-12-24 |
| 82842 |
0.5% Rhod-PE Encapsulated DOTMA:DOPE Liposomes,0.5% Rhod-PE包裹的DOTMA:DOPE脂质体 |
242 |
axc |
2024-12-24 |
| 82843 |
Tos-PEG3-CH2COOH,CAS号：1581248-63-6 |
149 |
h |
2024-12-24 |
| 82844 |
m-PEG4-CH2COOH,CAS号：16024-66-1 |
164 |
h |
2024-12-24 |
| 82845 |
0.5% NBD-DOPE Encapsulated DOTMA:Chol Liposomes,阳离子脂质体定制服务 |
193 |
axc |
2024-12-24 |
齐岳微信公众号
官方微信
库存查询